National survey of physicians’ perspectives on pharmacogenetic testing in solid organ transplantation

• Published in: Clinical transplantation 2020-10, Vol.34 (10), p.e14037-n/a
• Main Authors: Deininger, Kimberly M., Tsunoda, Shirley M., Hirsch, Jan D., Anderson, Heather, Lee, Yee Ming, McIlvennan, Colleen K., Page, Robert L., Tran, Jacinda N., Aquilante, Christina L.
• Format: Article
• Language: English
• Subjects: clinical implementation; personalized medicine; pharmacogenetics; surveys and questionnaires; transplantation
• ISSN: 0902-0063; 1399-0012
• DOI: 10.1111/ctr.14037

Introduction Our objective was to evaluate physicians' perspectives on the clinical utility of pharmacogenetic (PGx) testing in kidney, liver, heart, and lung transplantation (KLHL‐Tx). Methods A 36‐question web‐based survey was developed and administered to medical and surgical directors of US KLHL‐Tx centers. Results There were 82 respondents (10% response rate). The majority were men (78%), non‐Hispanic whites (70%), medical directors (72%), and kidney transplant physicians (35%). Although 78% of respondents reported having some PGx education, most reported lack of confidence in their PGx knowledge and ability to apply a PGx test. Participants reported mixed views about the clinical utility of PGx testing—most agreed with the efficacy of PGx testing, but not the benefits relative to the risks or standard of care. While 55% reported that testing was available at their institution, only 38% ordered a PGx test in the past year, most commonly thiopurine‐S‐methyltransferase. Physician‐reported barriers to PGx implementation included uncertainty about the clinical value of PGx testing and patient financial burden. Conclusion Together, our findings suggest prospective PGx research and pilot implementation programs are needed to elucidate the clinical utility and value of PGx in KLHL‐Tx. These initiatives should include educational efforts to inform the use of PGx testing.